Business Description
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US42366C3016
Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -41.92 | |||||
| Beneish M-Score | -5.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.2 | |||||
| 3-Year EBITDA Growth Rate | -16.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.1 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | -48.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 209.35 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.3 | |||||
| 9-Day RSI | 37.64 | |||||
| 14-Day RSI | 39.38 | |||||
| 6-1 Month Momentum % | -33.5 | |||||
| 12-1 Month Momentum % | -37.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 1.14 | |||||
| Days Sales Outstanding | 1116.19 | |||||
| Days Payable | 29456.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 | |||||
| Shareholder Yield % | -16.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.14 | |||||
| Operating Margin % | -15715.92 | |||||
| Net Margin % | -13952.74 | |||||
| FCF Margin % | -11706.97 | |||||
| ROE % | -189.75 | |||||
| ROA % | -124.35 | |||||
| ROIC % | -510.37 | |||||
| 3-Year ROIIC % | 87.57 | |||||
| ROC (Joel Greenblatt) % | -3435.16 | |||||
| ROCE % | -190.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 59.67 | |||||
| PB Ratio | 2.17 | |||||
| Price-to-Tangible-Book | 3.98 | |||||
| EV-to-EBIT | -0.29 | |||||
| EV-to-EBITDA | -0.29 | |||||
| EV-to-Revenue | 42.7 | |||||
| EV-to-Forward-Revenue | 42.94 | |||||
| EV-to-FCF | -0.36 | |||||
| Price-to-Median-PS-Value | 0.41 | |||||
| Price-to-Net-Current-Asset-Value | 23.51 | |||||
| Price-to-Net-Cash | 23.51 | |||||
| Earnings Yield (Greenblatt) % | -344.83 | |||||
| FCF Yield % | -154.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:AIM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AIM ImmunoTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.201 | ||
| EPS (TTM) ($) | -0.57 | ||
| Beta | 1.32 | ||
| Volatility % | 32.94 | ||
| 14-Day RSI | 39.38 | ||
| 14-Day ATR ($) | 0.021176 | ||
| 20-Day SMA ($) | 0.25605 | ||
| 12-1 Month Momentum % | -37.12 | ||
| 52-Week Range ($) | 0.2112 - 0.62 | ||
| Shares Outstanding (Mil) | 63.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AIM ImmunoTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AIM ImmunoTech Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AIM ImmunoTech Inc Frequently Asked Questions
What is AIM ImmunoTech Inc(AIM)'s stock price today?
The current price of AIM is $0.24. The 52 week high of AIM is $0.62 and 52 week low is $0.21.
When is next earnings date of AIM ImmunoTech Inc(AIM)?
The next earnings date of AIM ImmunoTech Inc(AIM) is 2024-11-15.
Does AIM ImmunoTech Inc(AIM) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers